The stock may react positively to the revenue beat and growth guidance, but investors should monitor the company's ability to control operating expenses as it scales commercial operations. The significant R&D revenue from partnerships provides near-term funding, but sustainable profitability will depend on commercial execution of upcoming launches.
Price Chart
Executive Summary
Ionis Pharmaceuticals reported full-year 2025 revenue of $944 million, exceeding guidance due to strong commercial sales and a $280 million upfront payment from Ono Pharmaceutical. While revenue grew 34% year-over-year, the company reported a larger GAAP operating loss of $382 million compared to $475 million in 2024, driven by investments in commercialization. The company provided 2026 guidance of $800-825 million in revenue, representing approximately 20% growth, with non-GAAP operating losses expected to be similar to 2025 levels excluding the one-time payment.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue was $944 million, up 34% from $705 million in 2024
- Revenue exceeded guidance due to TRYNGOLZA sales ($108 million) and a $280 million upfront payment from Ono Pharmaceutical
- GAAP operating loss was $382 million in 2025 vs $475 million in 2024
- 2026 revenue guidance is $800-825 million (approximately 20% growth)
- 2026 non-GAAP operating loss guidance is $500-550 million, similar to 2025 excluding the one-time payment
- Cash position was $2.7 billion as of December 31, 2025
Financial Impact
Revenue growth of approximately 20% in 2026 to $800-825 million, with operating losses remaining elevated
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| TRYNGOLZA | $108.00 | — |
| DAWNZERA | $8.00 | — |
| SPINRAZA royalties | $212.00 | -1.9% |
| WAINUA royalties | $49.00 | +145.0% |
Risk Factors
- Continued high operating losses despite revenue growth
- Dependence on successful commercialization of new products
- Regulatory risks for upcoming product approvals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-006718 |
| Document: ef20066495_8k.htm | 0001140361-26-006718 |
| Document: 0001140361-26-006718-index-headers.html | 0001140361-26-006718 |
| Document: 0001140361-26-006718-index.html | 0001140361-26-006718 |
| Document: 0001140361-26-006718.txt | 0001140361-26-006718 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $42.85 | awaiting T+20 | — | $42.93 (+0.20%) |
Oct 21, 2026 4d ago | 8-K | $43.91 | awaiting T+20 | — | $42.93 (−2.23%) |
Oct 21, 2026 4d ago | Institutional Cluster | $43.91 | awaiting T+20 | — | $42.93 (−2.23%) |
Sep 23, 2026 4w ago | 8-K | $43.93 $44.27 | ▲ +0.77% | ▲ +0.09% | $42.93 (−2.28%) |
Sep 4, 2026 7w ago | 8-K | $56.71 $44.00 | ▲ +22.41% | ▲ +24.13% | $42.93 (+24.30%) |
Sep 4, 2026 7w ago | 8-K | $58.09 $43.50 | ▼ −25.12% | ▼ −25.72% | $42.93 (−26.10%) |
Jul 31, 2026 12w ago | Insider Buy | $54.49 $60.36 | ▲ +10.77% | ▲ +9.53% | $42.93 (−21.21%) |
Jul 29, 2026 12w ago | 8-K | $54.04 $63.36 | ▲ +17.25% | ▲ +12.23% | $42.93 (−20.56%) |
Jul 9, 2026 15w ago | 8-K | $58.25 $56.56 | ▼ −2.90% | ▼ −5.33% | $42.93 (−26.30%) |
Jul 9, 2026 15w ago | Insider Cluster | $58.25 $56.56 | ▼ −2.90% | ▼ −5.33% | $42.93 (−26.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers